@article{1cc09235ae074a32af0c27da67e57ff2,
title = "Everything old is new again: are psychedelic medicines poised to take mental health by storm?",
author = "Raison, {Charles L.}",
note = "Funding Information: Based on these latter findings, as well as on a promising randomized trial in patients with cancer conducted by Charles Grob and colleagues at UCLA (6), when the door of possibilities opened a bit wider at the start of the 21st Century, researchers at Johns Hopkins and New York University (NYU) chose to use modern randomized, placebo-controlled, double-blind designs to examine whether the psychedelic agent psilocybin (the active ingredient in {\textquoteleft}magic mushrooms{\textquoteright}) might really help depressed and anxious cancer patients. These studies were done on financial shoe-strings, funded mostly by the Heffter Research Institute. They were conducted against an impressive range of obstacles, and they took a long time to complete. When asked why psilocybin was the chosen agent, several of the researchers ruefully told me, {\textquoteleft}Because it didn{\textquoteright}t contain the letters “L, S, D”.{\textquoteright} This honest confession spoke volumes about the",
year = "2018",
month = nov,
doi = "10.1111/acps.12975",
language = "English (US)",
volume = "138",
pages = "365--367",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "5",
}